Liminatus Pharma, Inc. Class A Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $346.5M
- Price
- $5.16
- % Change (Daily % change from the live per-ticker quote feed.)
- -8.35%
- Volume
- 116.0K
About
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Quick stats
Shares outstanding67.2M
Computed float669.8K
Float / shares1.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001971387
Websitehttps://liminatuspharma.com
AI Summary
AI-generated1/9
majorbearishreverse split
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Liminatus Pharma’s board approved a 1-for-50 reverse stock split, effective after market close on August 20, with split-adjusted trading commencing August 21.
The move reduces outstanding shares from approximately 67.2 million to roughly 1.34 million based on July 2 data; fractional shares will be rounded up.
Reverse splits of this magnitude are typically undertaken to regain compliance with minimum bid price requirements on the Nasdaq Capital Market.
Red flags
- reverse stock split signals listing compliance risk